Rare Disease Therapeutics

The story of Rare Disease Therapeutics, Inc. is the story of hopes vs. realities and the filling of the very specific and special medical needs of a small population of adults and children seeking life-preserving therapeutics for rare diseases. Many of these disease are not immediately recognizable to even the most astute physicians, thus the role of Rare Disease Therapeutics, Inc. must include creating awareness of such diseases and their diagnosis. Unfortunately, the realities are that all too few companies are willing to invest in low volume; low return research programsƒThus the needs of the few are lost to corporate profit/loss statements.

Rare Disease Therapeutics, Inc. on the other hand is a company built on the hope and premise of providing options where there are no options, and providing therapies where there are no therapies, through creative strategic alliances, as well as unique relationships with the government, research institutions, physicians, scientist, and manufactures.

Rare Disease Therapeutics, Inc. is a well established company founded in 1991 as Orphan Pharmaceuticals, U.S.A., Inc. Strategically located in Nashville, Tennessee the company changed its name to Rare Disease Therapeutics, Inc. in March 2001 to better describe its mission. Rare Disease Therapeutics, Inc. has a solid track record with multiple licensing agreements, a comprehensive global patient advocacy network, and significant success in drug development and approval.

The company is currently seeking strategic alliances in these therapeutic areas with partners who wish to access our experience and insights, as well as access to the following core competencies:

Orphan pharmaceutical development
Clinical development
Pre-approval distribution of Orphan drugs in accordance with the specific governmental regulations
Accelerated registration in the United States, Canada, Mexico, and South America

Effective and efficient, targeted sales and distribution
Secure and rapid delivery of products
Single source distribution
Pricing and reimbursement strategies to optimize product utilization
Orphan product regulatory maintenance

The company's major clinical expertise and licensing focus have been in rare diseases in the following therapeutic areas:

Oncology
Genetic disorders
Hematology

Metabolic diseases
Respiratory diseases
Poison control

Opportunistic infections
Hepatic diseases
Autoimmune diseases

In addition to the above cited therapeutic areas, Rare Disease Therapeutics, Inc. is also seeking current orphan products or low volume mature products that would be considered as orphans if these products were launched today.